IMUNON announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology, ASCO, annual meeting, to be held in Chicago from May 31st to June 4th. The abstract, titled “A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy when administered in combination with bevacizumab and neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer,” will be presented on June 3rd at the Gynecologic Cancer session.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
- IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
- Imunon announces site activation for IMNN-101 Phase 1 vaccine study
- Imunon sees cash runway to end of 2024
- Imunon appoints Stacy Lindborg as president, CEO